MC1833A1 - Derives acyles - Google Patents

Derives acyles

Info

Publication number
MC1833A1
MC1833A1 MC871895A MC1895A MC1833A1 MC 1833 A1 MC1833 A1 MC 1833A1 MC 871895 A MC871895 A MC 871895A MC 1895 A MC1895 A MC 1895A MC 1833 A1 MC1833 A1 MC 1833A1
Authority
MC
Monaco
Prior art keywords
hydrogen
compound
amino
manufacturing
salts
Prior art date
Application number
MC871895A
Other languages
English (en)
French (fr)
Inventor
Albrecht Harry
Chan Ka-Kong
Keith Dennis
Then Rudolf
Weigele Manfred
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MC1833A1 publication Critical patent/MC1833A1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D501/00Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/14Compounds having a nitrogen atom directly attached in position 7
    • C07D501/16Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
    • C07D501/207-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
    • C07D501/247-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
    • C07D501/26Methylene radicals, substituted by oxygen atoms; Lactones thereof with the 2-carboxyl group
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A61K47/552Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug one of the codrug's components being an antibiotic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Nanotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MC871895A 1986-07-03 1987-07-02 Derives acyles MC1833A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US88155586A 1986-07-03 1986-07-03

Publications (1)

Publication Number Publication Date
MC1833A1 true MC1833A1 (fr) 1988-06-03

Family

ID=25378717

Family Applications (1)

Application Number Title Priority Date Filing Date
MC871895A MC1833A1 (fr) 1986-07-03 1987-07-02 Derives acyles

Country Status (22)

Country Link
EP (1) EP0251330B1 (cs)
JP (1) JPH0730083B2 (cs)
KR (1) KR880001675A (cs)
CN (1) CN1021226C (cs)
AT (2) ATE97901T1 (cs)
AU (1) AU603364B2 (cs)
CS (2) CS270227B2 (cs)
DE (1) DE3788306D1 (cs)
DK (1) DK340387A (cs)
ES (1) ES2060583T3 (cs)
FI (1) FI88392C (cs)
HU (1) HU200185B (cs)
IE (1) IE61434B1 (cs)
IL (1) IL83046A (cs)
MC (1) MC1833A1 (cs)
MX (1) MX7189A (cs)
NO (1) NO168890C (cs)
NZ (1) NZ220914A (cs)
PH (1) PH23940A (cs)
PT (1) PT85246B (cs)
ZA (1) ZA874696B (cs)
ZW (1) ZW12787A1 (cs)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ227470A (en) * 1987-12-28 1991-06-25 Hoffmann La Roche Acyl derivatives of substituted cephem compounds; pharmaceutical compositions and methods for preparation and treatment
YU63689A (en) * 1988-03-31 1991-06-30 Hoffmann La Roche Acyl derivatives
EP0366640B1 (en) * 1988-10-24 1999-02-03 Procter & Gamble Pharmaceuticals, Inc. Antimicrobial fluoroquinolonyl cephems
EP0366189A3 (en) * 1988-10-24 1992-01-02 Norwich Eaton Pharmaceuticals, Inc. Novel antimicrobial lactam-quinolones
CA2001203C (en) * 1988-10-24 2001-02-13 Thomas P. Demuth, Jr. Novel antimicrobial dithiocarbamoyl quinolones
EP0366193A3 (en) * 1988-10-24 1992-01-08 Norwich Eaton Pharmaceuticals, Inc. Novel antimicrobial quinolonyl lactams
US5328908A (en) * 1988-10-24 1994-07-12 Procter & Gamble Pharmaceuticals, Inc. Antimicrobial quinolone thioureas
DE68929227T2 (de) * 1988-10-24 2001-05-31 Procter & Gamble Pharmaceuticals, Inc. Antimikrobielle Quinolonyllactamester
AU633867B2 (en) * 1989-02-02 1993-02-11 Eli Lilly And Company Delivery of cytotoxic agents
GB8907617D0 (en) * 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
KR100204987B1 (ko) * 1990-04-18 1999-06-15 제이코버스 코넬리스 레이서 항미생물성 퀴놀로닐 락탐
US5066800A (en) * 1990-04-27 1991-11-19 Hoffmann-La Roche Inc. Qunoline intermediates useful therein for synthesizing antibacterial compounds
US5244892A (en) * 1990-10-16 1993-09-14 Kyorin Pharmaceutical Co., Ltd. Cephem compounds, and antibacterial agents
GB9216759D0 (en) * 1992-08-07 1992-09-23 Finpael Spa Process for the production of 7-amino thiazolyl cephalosporins
DE4234330A1 (de) * 1992-10-12 1994-04-14 Bayer Ag Chinoloncarbonsäuren
US5728691A (en) * 1994-02-25 1998-03-17 Laboratorios Aranda S.A. De C.V. Quinolonylcarboxamidocephalosporin derivatives and pharmaceutical compositions containing them
MX9505113A (es) * 1995-12-07 1997-06-28 Aranda Lab Sa De Cv Derivados de cephalosporin fluoroquinolonatos y composiciones farmaceuticas que los contengan.
ES2784307T3 (es) * 2014-01-29 2020-09-24 Vyome Therapeutics Ltd Besifloxacina para el tratamiento del acné resistente

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3971778A (en) 1972-05-12 1976-07-27 Glaxo Laboratories Limited Cephalosporins having (α-etherified oximino)acylamido groups at the 7-position
HU168497B (cs) * 1972-12-18 1976-05-28
US4173199A (en) 1974-12-02 1979-11-06 Codama Holding S.A. Apparatus for reinforcing a fabric by applying a fluid reinforcing material thereto
DE2760123C2 (de) 1976-01-23 1986-04-30 Roussel-Uclaf, Paris 7-Aminothiazolyl-syn-oxyiminoacetamidocephalosporansäuren, ihre Herstellung und sie enthaltende pharmazeutische Zusammensetzungen
DE2716677C2 (de) 1977-04-15 1985-10-10 Hoechst Ag, 6230 Frankfurt Cephemderivate und Verfahren zu ihrer Herstellung
JPS5854157B2 (ja) 1977-06-10 1983-12-02 山之内製薬株式会社 セフアロスポリン化合物の新規誘導体ならびにその製造方法
JPS5630964A (en) * 1979-08-22 1981-03-28 Kyorin Pharmaceut Co Ltd Novel substituted quinolinecarboxylic acid and its preparation
US4266049A (en) 1980-02-20 1981-05-05 Eli Lilly And Company Process for 3-iodomethyl cephalosporins
FR2501209B1 (fr) * 1981-03-03 1986-07-04 Sanofi Sa Nouveaux derives des cephalosporines et medicaments antibiotiques contenant lesdits derives
SE440354B (sv) * 1981-02-19 1985-07-29 Kyorin Seiyaku Kk Kinolinkarboxylsyraderivat
FR2570702B1 (fr) * 1984-09-27 1987-01-09 Sanofi Sa Derives des cephalosporines, procedes d'obtention et leur application a titre d'antibiotiques
US4808711A (en) * 1985-01-21 1989-02-28 Sankei Pharmaceutical Co., Ltd. Cephalosporin derivatives
NZ227470A (en) * 1987-12-28 1991-06-25 Hoffmann La Roche Acyl derivatives of substituted cephem compounds; pharmaceutical compositions and methods for preparation and treatment

Also Published As

Publication number Publication date
CS496787A2 (en) 1989-10-13
ZW12787A1 (en) 1988-02-03
PT85246A (en) 1987-08-01
AU603364B2 (en) 1990-11-15
HU200185B (en) 1990-04-28
EP0251330A3 (en) 1989-06-28
FI88392C (fi) 1993-05-10
JPH0730083B2 (ja) 1995-04-05
IL83046A0 (en) 1987-12-31
NO168890C (no) 1992-04-15
CS395091A3 (en) 1992-12-16
KR880001675A (ko) 1988-04-26
NO168890B (no) 1992-01-06
AT391137B (de) 1990-08-27
EP0251330B1 (de) 1993-12-01
NO872770D0 (no) 1987-07-02
IE61434B1 (en) 1994-11-02
PH23940A (en) 1990-01-23
DK340387D0 (da) 1987-07-02
NO872770L (no) 1988-01-04
IL83046A (en) 1992-07-15
CS270227B2 (en) 1990-06-13
AU7500987A (en) 1988-01-07
NZ220914A (en) 1990-09-26
EP0251330A2 (de) 1988-01-07
HUT44258A (en) 1988-02-29
PT85246B (pt) 1990-03-30
FI872951A0 (fi) 1987-07-03
IE871765L (en) 1988-01-03
FI872951A7 (fi) 1988-01-04
DK340387A (da) 1988-01-04
ATE97901T1 (de) 1993-12-15
FI88392B (fi) 1993-01-29
MX7189A (es) 1993-08-01
ES2060583T3 (es) 1994-12-01
ZA874696B (en) 1988-01-04
CN1021226C (zh) 1993-06-16
JPS6322586A (ja) 1988-01-30
ATA264587A (de) 1990-02-15
DE3788306D1 (de) 1994-01-13
CN87105204A (zh) 1988-06-29

Similar Documents

Publication Publication Date Title
MC1833A1 (fr) Derives acyles
JP3553983B2 (ja) β−ラクタム化合物
US4760060A (en) 3-heteroaralkylthio carbacephem compounds and antibacterial pharmaceutical composition
MC1259A1 (fr) Derives acyles
MC2021A1 (fr) Preparation de derives acyliques utilisables notamment pour la fabrication de medicaments
AU621328B2 (en) 3(heterocyclyc carbonyl thio methyl)cephalosporin derivatives
CH621125A5 (cs)
HUT76340A (en) Pharmaceutical formulations containing a beta-lactamase inhibiting penem in combination with a beta-lactam antibiotic and their use in the treatment of bacterial infections
FR2610629A2 (fr) Nouveaux derives de l'acide 1-dethia 2-thia cephalosporanique, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les contenant
MC1422A1 (fr) Derives acyles
WO1996005205A1 (en) Novel cephem derivative
HUT53650A (en) Process for producing pharmaceutical compositions with beta-lactamase inhibiting effect and comprising stable oxapenem-3-carboxylic acids
JP2708576B2 (ja) カルバペネム誘導体
AU718679B2 (en) Cephem compounds
FI81103B (fi) Foerfarande foer framstaellning av acetoximetyl och -etoxikarbonyloxietyl penemestrar.
EP0188781B1 (en) 1-oxa-1-dethia-cephalosporin compounds and antibacterial agent comprising the same
IL109670A (en) Tricyclic cephem sulphones their preparation and pharmaceutical compositions containing them
JP2758413B2 (ja) カルバペネム化合物
MC1952A1 (fr) Derives acyles
MC1420A1 (fr) Derives de cephalosporine
EP0481441A2 (en) Novel cephem compounds, their preparation processes and antibacterial agents
KR100234014B1 (ko) 2-베타-알케닐-페남유도체 및 이의 제조방법
CA2274797A1 (en) Novel cephem derivatives
JP2004505896A (ja) 新規なセファロスポリン化合物およびその製造方法
MC1421A1 (fr) Derives acyles

Legal Events

Date Code Title Description
YP Annual fee paid